0.4102
price up icon3.64%   0.0144
after-market Dopo l'orario di chiusura: .41 -0.0002 -0.05%
loading
Precedente Chiudi:
$0.3958
Aprire:
$0.4
Volume 24 ore:
621.87K
Relative Volume:
0.61
Capitalizzazione di mercato:
$10.74M
Reddito:
-
Utile/perdita netta:
$-26.56M
Rapporto P/E:
-0.6311
EPS:
-0.65
Flusso di cassa netto:
$-22.29M
1 W Prestazione:
-4.38%
1M Prestazione:
-19.35%
6M Prestazione:
-46.34%
1 anno Prestazione:
-86.09%
Intervallo 1D:
Value
$0.3999
$0.425
Intervallo di 1 settimana:
Value
$0.36
$0.425
Portata 52W:
Value
$0.34
$3.199

BiomX Inc Stock (PHGE) Company Profile

Name
Nome
BiomX Inc
Name
Telefono
972 7 23942377
Name
Indirizzo
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Name
Dipendente
73
Name
Cinguettio
@BiomX_Inc
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
PHGE's Discussions on Twitter

Confronta PHGE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PHGE
BiomX Inc
0.4102 11.23M 0 -26.56M -22.29M -0.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

BiomX Inc Stock (PHGE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-04-15 Iniziato Ladenburg Thalmann Buy

BiomX Inc Borsa (PHGE) Ultime notizie

pulisher
Jul 21, 2025

What drives BiomX Inc. stock priceFree Stock Market Knowledge Sharing - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

BiomX Inc. Stock Analysis and ForecastExceptional market performance - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about BiomX Inc. stockUnmatched market gains - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Is BiomX Inc. a good long term investmentConsistent wealth multiplication - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Should I buy BiomX Inc. stock before earningsHigh Return Stock Alerts - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

How BiomX Inc. stock performs during market volatilityFree Signals Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes BiomX Inc. stock price move sharplyFree Access to Stock Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why BiomX Inc. stock attracts strong analyst attentionCapital Efficient Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

BiomX stock holds Buy rating at H.C. Wainwright as Phase 2b trial begins - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target - Investing.com India

Jul 15, 2025
pulisher
Jul 15, 2025

BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

BiomX Stock Drops 7.23% Despite Phase 2b Trial Milestone - AInvest

Jul 15, 2025
pulisher
Jul 14, 2025

BiomX announces successful initiation of Phase 2b trial - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Market Alert: BiomX Trading Surges Following Phase 2b Trial Initiation in Cystic Fibrosis Program - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Biomx Inc. shares fall 5.21% after-hours following the initiation of Phase 2b trial for BX004. - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

BiomX Initiates Phase 2b Trial for BX004, a Phage Therapy Targeting Antibiotic-Resistant Lung Infections in Cystic Fibrosis Patients. - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Biomx Inc. Announces Successful Initiation of Phase 2B Trial with First Patient Dosed in Bx004 Program in Patients with Cystic Fibrosis - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy - Investing.com Australia

Jul 14, 2025
pulisher
Jul 14, 2025

BiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis Treatment - MSN

Jul 14, 2025
pulisher
Jul 14, 2025

BiomX Doses First Patient in Phase 2b of Cystic Fibrosis Trial - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

BiomX begins phase 2b trial for phage therapy targeting CF infections - Investing.com Australia

Jul 14, 2025
pulisher
Jul 14, 2025

BiomX begins phase 2b trial for phage therapy targeting CF infections By Investing.com - Investing.com South Africa

Jul 14, 2025
pulisher
Jul 14, 2025

BiomX Inc. Initiates First Patient Dosing in Phase 2b Trial for BX004 Targeting Antibiotic-Resistant Lung Infections in Cystic Fibrosis Patients - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

BiomX Announces Successful Initiation of Phase 2b Trial - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

Breakthrough Cystic Fibrosis Treatment Enters Phase 2b Trial After 14% Complete Infection Clearance - Stock Titan

Jul 14, 2025
pulisher
Jul 12, 2025

BiomX (NYSEMKT:PHGE) Trading Down 43.3% – Here’s What Happened - Defense World

Jul 12, 2025
pulisher
Jul 08, 2025

BiomX Publishes Promising Phase 1b/2a Trial Results - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

BiomX’s “Bacteria-Eating Virus” Therapy Shows 500-Fold Reduction in Deadly CF Infections: Company Announces Major Scientific Validation in Key Publication - newsblaze.com

Jul 08, 2025
pulisher
Jul 08, 2025

BiomX announces publication on BX004 Phase 1b/2a Part 1 data - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

BiomX Announces Publication in Nature Communications of - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Nature Communications Validates BiomX's Breakthrough: 500-fold Bacteria Reduction in Cystic Fibrosis Trial - Stock Titan

Jul 08, 2025
pulisher
Jul 03, 2025

Red White & Bloom Brands Provides Update on Status of Annual Filings - The Globe and Mail

Jul 03, 2025
pulisher
Jun 26, 2025

This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret - FinancialContent

Jun 26, 2025
pulisher
Jun 26, 2025

This $13M Biotech Has $40M In Pentagon Funding Here's Why Biomx Could Be Biotech's Best-Kept Secret - MenaFN

Jun 26, 2025
pulisher
Jun 23, 2025

PHGE SEC FilingsBiomx Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 23, 2025
pulisher
Jun 17, 2025

BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections - citybuzz -

Jun 17, 2025
pulisher
Jun 16, 2025

BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says - FinancialContent

Jun 16, 2025
pulisher
Jun 09, 2025

BiomX Highlights Progress in Phage Therapy Advancements - TipRanks

Jun 09, 2025
pulisher
Jun 07, 2025

BiomX (NYSEAMERICAN:PHGE) Shares Down 4.3% – Here’s What Happened - Defense World

Jun 07, 2025
pulisher
May 31, 2025

Biomx stock plunges to 52-week low, hitting $0.47 By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

Biomx stock plunges to 52-week low, hitting $0.47 - Investing.com Australia

May 30, 2025
pulisher
May 29, 2025

BiomX (NYSEMKT:PHGE) Stock Price Down 32.6% – What’s Next? - Defense World

May 29, 2025
pulisher
May 26, 2025

Bacteriophage Therapy Market is Booming Worldwide |Enbiotix,Micreos,BiomX - openPR.com

May 26, 2025

BiomX Inc Azioni (PHGE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
Capitalizzazione:     |  Volume (24 ore):